Trial abstracts in the registry — page 3
700 documents of type trial abstract.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low10 Sep 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity and type 2 diabetes over 72 weeks. The Institute holds no reported primary result…
09 Sep 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Sep 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low26 Aug 2025 -
Event-driven cardiovascular outcome trial, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes randomising 9,650 participants over median 47.5…
Moderate25 Aug 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cognition randomising 194 participants over 96 weeks. Primary result: No significant…
Moderate16 Aug 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in knee osteoarthritis and obesity over as stated in the parent protocol. The Institute holds…
Very low30 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low25 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in type 2 diabetes over 52 weeks. The Institute holds no reported primary result for this…
17 Jul 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low14 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity randomising 610 participants over 48 weeks. Primary result: Mean change −14.0 % at 6…
Moderate09 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low08 Jul 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Jul 2025 -
Phase 1 ascending dose, phase 1 study of Exenatide in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low25 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes randomising 1,206 participants…
Moderate16 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low15 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Jun 2025 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low14 Jun 2025 -
Randomised crossover, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low08 Jun 2025 -
Randomised, open-label, active-controlled, phase 3 study of Tirzepatide in obesity randomising 751 participants over 72 weeks. Primary result: Mean change −20.2 % with…
High28 May 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in mash randomising 1,197 participants over 72 weeks for part 1. Primary result: Resolution in…
Moderate26 May 2025 -
Single-arm open-label, phase 3 study of Orforglipron in obesity and type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported…
Very low23 May 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low23 May 2025 -
Randomised, double-blind, placebo-controlled study of DSIP in sleep over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low14 May 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Survodutide in obesity randomising 387 participants over 46 weeks. Primary result: Mean change −18.7 % at…
Moderate12 May 2025 -
Observational study of Semax in cognition over not recorded. Primary result: As above. The Institute grades all claims for this compound very low certainty for absence…
12 May 2025 -
Phase 1 ascending dose, phase 1 study of Amycretin in obesity randomising 125 participants over up to 36 weeks. Primary result: Exploratory weight reduction of…
Low04 May 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over 52 weeks. Primary result: Directionally consistent with the…
High24 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no…
Very low24 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low17 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low13 Apr 2025 -
Observational, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low09 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity randomising 731 participants over median 104 weeks. Primary result…
Moderate07 Apr 2025 -
Phase 1 ascending dose, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low31 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Sermorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over up to 20 weeks. The Institute holds no reported primary result for this record and publishes no…
Very low19 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes randomising 319 participants over 24 weeks. Primary result: A reduction of…
Moderate14 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low12 Mar 2025
page 3 of 18